A decline in depression treatment following FDA antidepressant warnings largely explains racial/ethnic disparities in prescription fills

Depression and Anxiety

Volumn 34, Issue 12, 2017, Pages 1147-1156

  Carson, Nicholas J ^a   Progovac, Ana M ^a   Wang, Ye ^b   Cook, Benjamin L ^a  

^a CAMBRIDGE HEALTH ALLIANCE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

antidepressants; child adolescent; depression; minority groups

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; AGE DISTRIBUTION; ANXIETY DISORDER; ARTICLE; CHILD; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MANUFACTURE; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MENTAL HEALTH; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SCHOOL CHILD; AFRICAN AMERICAN; CAUCASIAN; FOOD AND DRUG ADMINISTRATION; HISPANIC; PRACTICE GUIDELINE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADOLESCENT; AFRICAN AMERICANS; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DEPRESSION; DEPRESSIVE DISORDER; DRUG PRESCRIPTIONS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOXETINE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; MALE; MEDICAID; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85030452635     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22681     Document Type: Article

References (36)

1. Bach, P. B., Pham, H. H., Schrag, D., Tate, R. C., & Hargraves, J. L. (2004). Primary care physicians who treat blacks and whites. New England Journal of Medicine, 351(6), 575–584.
2. Bhatia, S. K., Rezac, A. J., Vitiello, B., Sitorius, M. A., Buehler, B. A., & Kratochvil, C. J. (2008). Antidepressant prescribing practices for the treatment of children and adolescents. Journal of Child and Adolescent Psychopharmacology, 18(1), 70–80.
3. Busch, S. H., Frank, R. G., Leslie, D. L., Martin, A., Rosenheck, R. A., Martin, E. G., & Barry, C. L. (2010). Antidepressants and suicide risk: How did specific information in FDA safety warnings affect treatment patterns? Psychiatric Services, 61(1), 11–16.
4. Cook, B. L., Zuvekas, S. H., Carson, N., Wayne, G. F., Vesper, A., & McGuire, T. G. (2014). Assessing racial/ethnic disparities in treatment across episodes of mental health care. Health Services Research, 49(1), 206–229.
5. Crystal, S., Akincigil, A., Bilder, S., & Walkup, J. T. (2007). Studying prescription drug use and outcomes with Medicaid claims data: Strengths, limitations, and strategies. Medical Care, 45(10), S58–S65.
6. Cummings, J. R., & Druss, B. G. (2011). Racial/ethnic differences in mental health service use among adolescents with major depression. Journal of the American Academy of Child & Adolescent Psychiatry, 50(2), 160–170.
7. DePetris, A. E., & Cook, B. L. (2013). Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups. Psychiatric Services, 64(5), 466–471.
8. Dusetzina, S. B., Busch, A. B., Conti, R. M., Donohue, J. M., Alexander, G. C., & Huskamp, H. A. (2012). Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety, 21(12), 1251–1260.
9. Dusetzina, S. B., Cook, B. L., Busch, A. B., Alexander, G. C., & Huskamp, H. A. (2013). Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia. Psychiatric Services, 64(1), 83–87.
10. Dusetzina, S. B., Higashi, A. S., Dorsey, E. R., Conti, R., Huskamp, H. A., Zhu, S.,.. Alexander, G. C. (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: A systematic review. Medical Care, 50(6), 466–478.
11. Evans, E., Hawton, K., Rodham, K., & Deeks, J. (2005). The prevalence of suicidal phenomena in adolescents: A systematic review of population-based studies. Suicide and Life-Threatening Behavior, 35(3), 239–250.
12. Geller, B., Reising, D., Leonard, H. L., Riddle, M. A., & Walsh, B. T. (1999). Critical review of tricyclic antidepressant use in children and adolescents. Journal of the American Academy of Child & Adolescent Psychiatry, 38(5), 513–516.
13. Gomez, S. L., Kelsey, J. L., Glaser, S. L., Lee, M. M., & Sidney, S. (2005). Inconsistencies between self-reported ethnicity and ethnicity recorded in a health maintenance organization. Annals of Epidemiology, 15(1), 71–79.
14. Haider, M., & Kreps, G. L. (2004). Forty years of diffusion of innovations: Utility and value in public health. Journal of Health Communication, 9(Suppl 1), 3–11.
15. Hammad, T. A., Neyarapally, G. A., Iyasu, S., Staffa, J. A., & Dal Pan, G. (2013). The future of population-based postmarket drug risk assessment: A regulator's perspective. Clinical Pharmacology & Therapeutics, 94(3), 349–358.
16. Hirsch, G. S. (2014). Antidepressants (SSRIs) and their use in children and adolescents. Retrieved from https://www.aboutourkids.org/articles/antidepressants_ssris_their_use_in_children_adolescents.
17. Horvitz-Lennon, M., Volya, R., Donohue, J. M., Lave, J. R., Stein, B. D., & Normand, S. L. (2014). Disparities in quality of care among publicly insured adults with schizophrenia in four large U.S. states, 2002–2008. Health Services Research, 49(4), 1121–1144.
18. Kaiser Family Foundation. Health Insurance Coverage of Children 0–18: 2015. State Health Facts. http://kff.org/other/state-indicator/children-0-18/?currentTimeframe=0: Kaiser Family Foundation; Accessed April 3, 2017.
19. Katz, R. (2003). NDA 18–936/S-064, Rockville, MD. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/18936se5-064ltr.pdf
20. Keeler, E. B., Manning, W. G., & Wells, K. B. (1988). The demand for episodes of mental health services. Journal of Health Economics, 7(4), 369–392.
21. Libby, A. M., Brent, D. A., Morrato, E. H., Orton, H. D., Allen, R., & Valuck, R. J. (2007). Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Psychiatry, 164(6), 884–891.
22. Lu, C. Y., Soumerai, S. B., Ross-Degnan, D., Zhang, F., & Adams, A. S. (2010). Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Medical Care, 48(1), 4–9.
23. Lu, C. Y., Zhang, F., Lakoma, M. D., Madden, J. M., Rusinak, D., Penfold, R. B.,.. Soumerai, S. B. (2014). Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: Quasi-experimental study. BMJ, 348, g3596.
24. Mayo Foundation for Medical Education and Research (2011). Depression medication choice. Mayo clinic shared decision making. Rochester, MN. National Resource Center.
25. Merikangas, K. R., He, J. P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L.,.. Swendsen, J. (2010). Lifetime prevalence of mental disorders in U.S. adolescents: Results from the National Comorbidity Survey Replication—Adolescent supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry, 49(10), 980–989.
26. Olfson, M., Marcus, S. C., & Druss, B. G. (2008). Effects of Food and Drug Administration warnings on antidepressant use in a national sample. Archives of General Psychiatry, 65(1), 94–101.
27. Olson, A. L., Kelleher, K. J., Kemper, K. J., Zuckerman, B. S., Hammond, C. S., & Dietrich, A. J. (2001). Primary care pediatricians' roles and perceived responsibilities in the identification and management of depression in children and adolescents. Ambulatory Pediatrics, 1(2), 91–98.
28. Penfold, R. B., & Zhang, F. (2013). Use of interrupted time series analysis in evaluating health care quality improvements. Academic Pediatrics, 13(6 Suppl), S38–S44.
29. Ramsay, C. R., Matowe, L., Grilli, R., Grimshaw, J. M., & Thomas, R. E. (2003). Interrupted time series designs in health technology assessment: Lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care, 19(4), 613–623.
30. Rector, T. S., Adabag, S., Cunningham, F., Nelson, D., & Dieperink, E. (2016). Outcomes of citalopram dosage risk mitigation in a veteran population. American Journal of Psychiatry, 173(9), 896–902.
31. Saloner, B., Carson, N., & Cook, B. L. (2014). Episodes of mental health treatment among a nationally representative sample of children and adolescents. Medical Care Research and Review, 71(3), 261–279.
32. Shah, N. D., Montori, V. M., Krumholz, H. M., Tu, K., Alexander, G. C., & Jackevicius, C. A. (2010). Responding to an FDA warning–geographic variation in the use of rosiglitazone. New England Journal of Medicine, 363(22), 2081–2084.
33. Tansella, M., Micciolo, R., Biggeri, A., Bisoffi, G., & Balestrieri, M. (1995). Episodes of care for first-ever psychiatric patients. A long-term case-register evaluation in a mainly urban area. British Journal of Psychiatry, 167(2), 220–227.
34. U.S. Food and Drug Administration (FDA). (2014). National drug code directory. from Retrieved from https://www.fda.gov/drugs/informationondrugs/ucm142438.htm
35. Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002). Segmented regression analysis of interrupted time series studies in medication use research. Journal of Clinical Pharmacy and Therapeutics, 27(4), 299–309.
36. Whittington, C. J., Kendall, T., Fonagy, P., Cottrell, D., Cotgrove, A., & Boddington, E. (2004). Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet, 363(9418), 1341–1345.